Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. Dezember 2023 09:11 ET | Quelle: Wisekey International Holding Ltd.

WISeKey’s Subsidiary WISeSat.Space Reinforces Space Strategy Through Strategic Partnerships and Innovative Projects

WISeKey’s Subsidiary WISeSat.Space Reinforces Space Strategy Through Strategic Partnerships and Innovative Projects Geneva, Switzerland – December 11, 2023 – WISeKey International Holding Ltd....
11. Dezember 2023 04:00 ET | Quelle: Kuntarahoitus Oyj

Kuntarahoitus laskee liikkeeseen 50 miljoonan euron lisäyksen viitelainaan osana joukkovelkakirjalainaohjelmaa

Kuntarahoitus OyjPörssitiedote11.12.2023 klo 11.00 Kuntarahoitus laskee liikkeeseen 50 miljoonan euron lisäyksen viitelainaan osana joukkovelkakirjalainaohjelmaa Kuntarahoitus Oyj laskee 12.12.2023...
11. Dezember 2023 04:00 ET | Quelle: Municipality Finance Plc

Municipality Finance issues a EUR 50 million tap under its MTN programme

Municipality Finance PlcStock exchange release 11 December 2023 at 11:00 am (EET) Municipality Finance issues a EUR 50 million tap under its MTN programme On 12 December 2023 Municipality Finance...
11. Dezember 2023 01:15 ET | Quelle: Basilea Pharmaceutica AG

Basilea gibt FDA-Zulassung zur erweiterten Verwendung von Antipilzmittel Cresemba® (Isavuconazol) in den USA bei Kindern mit invasiver Aspergillose und invasiver Mukormykose bekannt

Allschwil, 11. Dezember 2023 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an...
11. Dezember 2023 01:15 ET | Quelle: Basilea Pharmaceutica AG

Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis

Allschwil, Switzerland, December 11, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe...
11. Dezember 2023 01:15 ET | Quelle: Novartis Pharma AG

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)

Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;...
11. Dezember 2023 01:00 ET | Quelle: F. Hoffmann-La Roche Ltd

New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma

Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of...
10. Dezember 2023 19:30 ET | Quelle: Novartis Pharma AG

Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)

APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to...
10. Dezember 2023 12:00 ET | Quelle: Molecular Partners

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting

Initial antitumor activity observed in early MP0533 dose-escalation cohorts, with a previously undisclosed complete response (CR) observed in dose range four, in addition to the previously reported...
09. Dezember 2023 11:30 ET | Quelle: F. Hoffmann-La Roche Ltd

New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A

Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years...

Vorherige Seite

Nächste Seite